Correction: Role of novel histone modifications in cancer

Muthu K. Shanmugam; Frank Arfuso; Surendar Arumugam; Arunachalam Chinnathambi; Jinsong Bian; Sudha Warrier; Ling Zhi Wang; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi; Manikandan Lakshmanan

doi:10.18632/oncotarget.25152

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Role of novel histone modifications in cancer

PDF | How to cite

Oncotarget. 2018; 9:19460-19460. https://doi.org/10.18632/oncotarget.25152

Metrics: PDF 3133 views | ?

Muthu K. Shanmugam¹, Frank Arfuso², Surendar Arumugam¹⁰, Arunachalam Chinnathambi³, Jinsong Bian¹, Sudha Warrier⁴, Ling Zhi Wang^1,5, Alan Prem Kumar^1,5,6,7,8, Kwang Seok Ahn⁹, Gautam Sethi¹ and Manikandan Lakshmanan^10,11

¹Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
²Stem Cell and Cancer Biology Laboratory, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia
³Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
⁴Division of Cancer Stem Cells and Cardiovascular Regeneration, School of Regenerative Medicine, Manipal Academy of Higher Education (MAHE), Bangalore, India
⁵Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
⁶Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
⁷National University Cancer Institute, National University Health System, Singapore, Singapore
⁸Department of Biological Sciences, University of North Texas, Denton, Texas, USA
⁹College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul, Korea
¹⁰Institute of Molecular and Cell Biology, A*STAR, Biopolis Drive, Proteos, Singapore, Singapore
¹¹Department of Pathology, National University Hospital Singapore, Singapore, Singapore

Published: April 10, 2018

This article has been corrected: The correct author name is given below:

Jinsong Bian

Original article: Oncotarget. 2018; 9:11414-11426. DOI: https://doi.org/10.18632/oncotarget.23356.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25152

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Role of novel histone modifications in cancer